Аксалимоген филолисбак

Axalimogene filolisbac

МНН

Rec. INN (наименование, зарегистрированное ВОЗ)

CAS

1587258-09-0

Химическое название

A live attenuated recombinant strain of Listeria monocytogenes (Lm) bacterium bioengineered to secrete an antigen-adjuvant fusion (tLLO-E7) protein consisting of non-hemolytic listeriolysin O (truncated LLO, tLLO) fused to the human papilloma virus-16 (HPV-16) E7 protein, contained within the multi-copy plasmid pGG-55. The bacterial strain used, XFL-7, had been attenuated by excision of the essential transcription activator gene for virulence gene expression prfA (10403S ∆ prfA) and complemented with a mutated, less active prfA to maintain in vivo retention. In plasmid pGG-55, the Lm hly promoter drives the expression of fusion protein tLLO-E7, an approximately 67-kDa protein. The tLLO fragment of the fusion gene codes for the first 440 amino acids of fulllength listeriolysin and is genetically fused to the E7 gene using the restriction site XhoI. The plasmid pGG55 is retained in XFL-7 in vivo due to the expression of the mutated PrfA protein.

Структура

Структура Аксалимоген филолисбак

Иностранные названия

Поделиться этой страницей

Подробнее по теме

Узнайте дополнительные сведения о действующем веществе Аксалимоген филолисбак: